-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Stoke Therapeutics, Raises Price Target to $35

Benzinga·01/05/2026 13:24:14
Listen to the news
Chardan Capital analyst Keay Nakae maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $24 to $35.